laboratory equipment and services

Luxembourg Eurofins Core Tender

📄 Tender ID: 464532486 📅 Published: 09 Aug 2021

📋 Tender Overview

Strong growth of revenues resulting in a record six month period with EUR 3272m revenues in H1 2021 up 41 vs. H1 2020 thanks to strong growth of Eurofins Core Business excluding COVID-19 related clinical testing and reagent revenues and sustained revenues from COVID-19 testing and reagents close to EUR 750m.The Core Business delivered strong organic growth13 in H1 2021 17 year-on-year despite some of Eurofins businesses remaining affected by lockdowns during H1 2021.Just looking at H1 2021 vs. H1 2020 however which is an easy comparable affected by temporary lockdowns does not give the best picture of long-term organic growth and business recovery. We thus provide comparison with the pre-pandemic period of H1 2019 as an additional data point. Core Business organic growth was 16 in H1 2021 vs. H1 2019 and close to 13 vs. H1 2019 corrected for the EUR 62m estimated missing revenues from the cyber-attack of 2 June 2019.With organic revenues 13 above H1 2019 in H1 2021 Eurofins Core Business is once again leading the TIC industry in terms of organic growth. Since the last pre-pandemic comparable period H1 2019 the Core Business has delivered a CAGR of over 6 compared with an average of about 0.5 for the three historic TIC leaders. Eurofins has done a very modest level of acquisitions in 2019 2020 and H1 2021 and this again confirms that acquisitions do not boost organic growth. In fact integration efforts rather reduce organic growth.The strong growth of the Core Business in the first half of 2021 comes in part from a faster recovery than expected. At the time of FY 2020 results publication we estimated that EUR 250m revenues had been lost in FY 2020 due to the impact of COVID-19 lockdowns and travel restrictions and the objective was to recover these revenues by 2022. It appears that these revenues have been largely recovered now earlier than forecast and were complemented by further organic growth of more than 5.In Q2 2021 Eurofins Core Business achieved organic growth of 25 19 vs. Q2 2019 and close to 13 vs. Q2 2019 corrected for the EUR 62m estimated missing revenues from the cyber-attack of June 2019 confirming the recovery and fast organic growth of the Core Business which is tracking well above the Groups 5 annual objective since 2019 in spite of some remaining drag from the pandemic.Total revenues including COVID-19 testing and reagents grew 41 in H1 2021 and 43 organically well above initial expectations.Record adjusted1 EBITDA3 of EUR 1008m in H1 2021 104 year-on-year representing a 30.8 adjusted EBITDA margin.Strong cash flow generation with Free Cash Flow to the Firm10 of EUR 489m 55 year-on-year which coupled with controlled capital expenditure enabled the Group to further lower its leverage to 1.0x net debtlast 12 months proforma adjusted EBITDA despite significant one-off bond repurchase costs in H1 2021.Refinancing exercises carried out in H1 2021 enabled the Group to secure a EUR 750m 10-year bond with a coupon below 1 and will bring the average cost of financing below 1.8 from the second half of 2021 onwards as the Group fully repaid in May and June 2021 its 2022 and 2023 Eurobonds and successfully purchased a significant portion of its 2024 and 2026 Eurobonds which were bearing much higher interest rates.Second investment grade credit rating from Fitch Ratings after the one secured with Moodys last year.Reported basic earnings per share EPS8 increased by 317 to a record EUR 2.17 in H1 2021 compared to EUR 0.52 in H1 2020.The growth in the Core Business was broad based and across business lines. Notable product launches and innovation includedHighly innovative rapid testing methods including for the identification of sugars and the organic certification of productsNew proprietary advanced testing methods to expand Clinical Diagnostics services for transplant patientsDifferentiated services technologies in Environment Testing including a new automated and robotised PFAS testing method supporting the lowest detection limits globallyTruGraf approved with Humana for in-network coverage of Medicare kidney transplant patients effective August 1 2021.Continued commitment and innovation to fight the COVID-19 pandemicOver 25 million COVID-19 PCR tests completed since the start of the pandemicOver 125000 SARS-CoV-2 samples sequenced from 23 countries since our press release on 28 December 2020Broad network of over 1000 testing centres developed in Europe to facilitate summer travelling through SAFER@WORK.Eurofins has made further progress in H1 towards the completion of its infrastructure and operational excellence programmes.Outlook As outlined previously the Groups 2021 objectives set on March 1 2021 were likely to be significantly exceeded. The uncertainties surrounding new variants and public health responses still make precise predictions impossible but if Eurofins were to generate only EUR 1 billion revenues from COVID-19 testing and reagents in FY 2021 so only EUR 250 million in H2 and 5 organic growth in H2 2021 for its Core Business the annual revenues for FY 2021 would exceed EUR 6150m. This can be taken as an upgraded revenue objective for FY 2021. On this basis adjusted EBITDA would likely exceed EUR 1700m in FY 2021. Eurofins thus now upgrades FY 2021 objectives for revenues by 13 to EUR 6150m and for adjusted EBITDA by 36 to EUR 1700m all at average H1 2021 exchange rates. Should COVID-19 testing continue at high levels in Q4 2021 this could once again be significantly exceeded.

🔍 Key Information

📄
Tender Reference No.
464532486
📅
Publication Date
09 Aug 2021
🌐
Sector
laboratory equipment and services
📝
Notice Type
News
📍
Location
Luxembourg

📁 Documents & Downloads

No documents found

🏷️ CPV

No CPV found

Need help with this bid?

Our bid experts can help you find, evaluate & win more tenders.

🎧 Talk to Bid Expert
🕒 Submission deadline
0
days remaining · 09 Aug 2021
🔔 Set Alert

🧭 Quick Facts

Authority N/A
Country Luxembourg
State / UT N/A
Tender Type Procurement News
Currency N/A
Similar Tenders
Loading similar tenders…